Skip to main content

Table 2 Mann–Whitney U test analysis of SF-12 0–100 scores, biochemical markers and symptom scores between women vs. men and treatment initiated vs. treatment not initiated

From: Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study

  N Median Quartiles25–75% P-valueMann–Whitney Cohen’s d Mean Min–max SD
SF-12 PCS
 Treatment initiated 25 87 64–96 .045* .50 75 19–96 26
 Treatment not initiated 35 71 38–90    61 6–100 30
Bodily pain
 Treatment initiated 25 100 75–100 .013* .59 83 0–100 30
 Treatment not initiated 36 75 31–100    64 0–100 34
Social functioning
 Women 33 75 38–100 .041* .59 70 0–100 34
 Men 28 100 75–100    87 25–100 23
Biochemical markers
 Uroporphyrinsa
  Women 33 557 286–941 .022* .62 625 145–1528 370
  Men 28 369 215–531    426 128–1018 263
Symptoms
 Symptoms scoreb
  Women 33 6 3–8 .042* .79 6 0–15 3
  Men 28 3 2–6    4 1–9 2
  1. Mann–Whitney U test was performed for all variables in all groups. Only results associated with a p-value < 0.05 are shown. Groups tested: familial PCT vs. sporadic PCT, low-to-moderate alcohol consumption vs. moderate-to-high alcohol consumption, smoking vs. no smoking
  2. The following SF-12 domains were also tested but no significant differences between groups were identified: MCS, role physical, general health, vitality, role emotional, mental health
  3. aUroporphyrins: urinary excretion of uroporphyrins in nmol/mmol creatinine
  4. bSymptoms: numerical score based on number and localization of symptoms (0–25)
  5. * p < .05; ** p < .01